NCT05308264 - Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Low Risk Myelodysplastic Syndromes

Interventions

DRUG

R906289 Monosodium (R289 Na)

Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)

Trial Locations (15)

10029

RECRUITING

Ichan School of Medicine at Mount Sinai, New York

27705

NOT_YET_RECRUITING

Duke Cancer Institute, Durham

33136

RECRUITING

University of Miami, Miami

33140

WITHDRAWN

Mount Sinai Medical Center, Miami Beach

43210

NOT_YET_RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

44195

RECRUITING

Cleveland Clinic, Cleveland

63110

NOT_YET_RECRUITING

WashU Medicine, St Louis

75390

RECRUITING

University of Texas, Southwestern, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

84009

RECRUITING

Intermountain Healthcare, Salt Lake City

90095

RECRUITING

University of California, Los Angeles, Los Angeles

92868

RECRUITING

University of California, Irvine, Orange

94304

NOT_YET_RECRUITING

Stanford Cancer Institute, Palo Alto

07601

RECRUITING

Oncology Clinical Research Referral Office, Hackensack

09083

WITHDRAWN

Rutgers Cancer Institute of New Jersey, New Brunswick